☆ 4.7 Meeting Abstract

Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).

JOURNAL OF CLINICAL ONCOLOGY (2019)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 37, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2019.37.15_suppl.1054

Keywords

Funding

Sanofi

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper